BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

Table 1 Clinico-pathologic characteristics of the 254 EOC patients

Characteristic	BTLA
Characteristic	Non-detectable (n = 105)	Detectable (n = 149)	p value
Follow-up period [mean ± SD, months]	38.2 ± 31.5
Age [mean ± SD, years]	53.3 ± 11.8
FIGO stage^a [early/advanced, cases]	33/72	28/121	0.025
Histology^a [serous/mucinous/clear cell /endometrioid/undifferentiated, cases]	57/0/13/24/11	90/1/14/24/20	0.471
Tumor grade^a,c [1&2/3, cases]	16/86	19/124	0.712
Postoperative residual tumor^a [< 1 cm/≥1 cm, cases]	65/40	79/70	0.198
HVEM^b [median, range]	1.05 (0.01–79.0)	1.52 (0.04–78.2)	0.135
BTLA^b [median, range]	0	0.16 (0.007–24.3)	< 0.001
Disease recurrence^a [yes/no, cases]	48/57	108/41	< 0.001
Disease-related death^a [yes/no, cases]	18/87	59/90	< 0.001

Abbreviations: EOC epithelial ovarian carcinoma; SD standard deviation; FIGO International Federation of Gynecology and Obstetrics; HVEM herpesvirus entry mediator; BTLA B and T lymphocyte attenuator
^a By Chi-square test
^b By Mann-Whitney test
^c Data unavailable for nine patients